{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:55:12Z","timestamp":1784120112469,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Although the approval of new therapies includes only one agent in 50\u00a0years, a number of promising new drugs are in development. Lupus nephritis is a dreaded complication of SLE as it is associated with significant morbidity and mortality. Advancing the treatment of lupus nephritis requires well-designed clinical trials and this can be challenging in SLE. The major obstacles involve identifying the correct population of patients to enroll and ensuring that a clinically appropriate and patient-centered endpoint is being measured. In this review, we will first discuss the clinical utility of endpoints chosen to represent lupus nephritis in global disease activity scales. Second, we will review completed and active trials focused on lupus nephritis and discuss the endpoints chosen. There are many important lessons to be learned from existing assessment tools and clinical trials. Reviewing these points will help ensure that future efforts will yield meaningful disease activity measures and well-designed clinical trials to advance our understanding of lupus management.<\/jats:p>","DOI":"10.1186\/s13075-015-0621-6","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T12:04:02Z","timestamp":1430136242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Kristin M","family":"Corapi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William F","family":"Pendergraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin 3rd HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614\u20139.","journal-title":"N Engl J Med"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2215\/CJN.03290412","volume":"8","author":"BH Rovin","year":"2013","unstructured":"Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, et al. Lupus nephritis: induction therapy in severe lupus nephritis - should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013;8:147\u201353.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110\u201321.","journal-title":"N Engl J Med."},{"key":"621_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.berh.2013.07.004","volume":"27","author":"FA Houssiau","year":"2013","unstructured":"Houssiau FA, Lauwerys BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol. 2013;27:319\u201328.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"621_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.080625","volume":"36","author":"MM Ward","year":"2009","unstructured":"Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996\u20132004. J Rheumatol. 2009;36:63\u20137.","journal-title":"J Rheumatol."},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.30293","volume":"63","author":"KH Costenbader","year":"2011","unstructured":"Costenbader KH, Desai A, Alarc\u00f3n GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63:1681\u20138.","journal-title":"Arthritis Rheum."},{"key":"621_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.05040513","volume":"9","author":"SV Parikh","year":"2014","unstructured":"Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 2014;9:279\u201384.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/ndt\/gfg345","volume":"18","author":"RG Barr","year":"2003","unstructured":"Barr RG, Seliger S, Appel GB, Zuniga R, D\u2019Agati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race\/ethnicity. Nephrol Dial Transplant. 2003;18:2039\u201346.","journal-title":"Nephrol Dial Transplant."},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/art.22894","volume":"57","author":"GS Cooper","year":"2007","unstructured":"Cooper GS, Treadwell EL, St Clair EW, Gilkeson GS, Dooley MA. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum. 2007;57:993\u20139.","journal-title":"Arthritis Rheum."},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2215\/CJN.00490109","volume":"4","author":"KL Gibson","year":"2009","unstructured":"Gibson KL, Gipson DS, Massengill SA, Dooley MA, Primack WA, Ferris MA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 2009;4:1962\u20137.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0961203310371161","volume":"19","author":"G Obermoser","year":"2010","unstructured":"Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus. 2010;19:1012\u20139.","journal-title":"Lupus."},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013010026","volume":"24","author":"M Lech","year":"2013","unstructured":"Lech M, Anders H-J. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24:1357\u201366.","journal-title":"J Am Soc Nephrol."},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2215\/CJN.05870612","volume":"8","author":"S Kalloo","year":"2013","unstructured":"Kalloo S, Aggarwal N, Mohan P, Radhakrishnan J. Lupus nephritis: treatment of resistant disease. Clin J Am Soc Nephrol. 2013;8:154\u201361.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR14","doi-asserted-by":"crossref","unstructured":"Balow JE. Renal manifestations of systemic lupus erythematosus. In: Primer on Kidney Diseases. Edited by Greenburg A. Philadelphia, PA: Saunders Elsevier; 2009:208\u201313.","DOI":"10.1016\/B978-1-4160-5185-5.00024-9"},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241\u201350.","journal-title":"J Am Soc Nephrol."},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/annrheumdis-2013-203790","volume":"73","author":"DJ Birmingham","year":"2014","unstructured":"Birmingham DJ, Shidham G, Perna A, Fine DM, Bissell M, Rodby R, et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis. 2014;73:475\u20136.","journal-title":"Ann Rheum Dis."},{"key":"621_CR17","unstructured":"Food and Drug Administration. Guidance for Industry-Systemic Lupus Erythematosus- Developing Medical Products for Treatment. http:\/\/google2.fda.gov\/search?q=lupus+trials&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=\u2212archive%3AYes&output=xml_no_dtd&getfields=*. Accessed 10 March 2014."},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1002\/acr.20572","volume":"63","author":"J Romero-Diaz","year":"2011","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2\u00a0K), and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI). Arthritis Care Res. 2011;63:S37\u201346.","journal-title":"Arthritis Care Res."},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1191\/096120301678646146","volume":"10","author":"SC Bae","year":"2001","unstructured":"Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10:405\u20139.","journal-title":"Lupus."},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1191\/0961203303lu332oa","volume":"12","author":"EW Karlson","year":"2003","unstructured":"Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus. 2003;12:280\u20136.","journal-title":"Lupus."},{"key":"621_CR21","unstructured":"Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54:421\u201332."},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/art.1780170602","volume":"6","author":"AD Steinberg","year":"1974","unstructured":"Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 1974;6:923\u201337.","journal-title":"Arthritis Rheum."},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1191\/096120399680411290","volume":"8","author":"MH Liang","year":"1999","unstructured":"Liang MH, Corzillius M, Bae SC, Fortin P, Esdaile JM, Abrahamowicz M. A conceptual framework for clinical trials in SLE and other multisystem diseases. Lupus. 1999;8:570\u201380.","journal-title":"Lupus."},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156\u201362.","journal-title":"N Engl J Med."},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103\u201312.","journal-title":"J Am Soc Nephrol."},{"key":"621_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie R, Nicholls K, Cheng T-T, Houssiau F, Burgos-Vargas R, Chen S-L, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheum. 2014;66:379\u201389.","journal-title":"Arthritis Rheum."},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219\u201328.","journal-title":"N Engl J Med."},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215\u201326.","journal-title":"Arthritis Rheum."},{"key":"621_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O\u2019Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971\u201380.","journal-title":"N Engl J Med."},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886\u201395.","journal-title":"N Engl J Med."},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/BOR.0b013e328363f4f2","volume":"25","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF. Challenges and opportunities in SLE clincal trials. Curr Opin Rheumatol. 2013;25:606\u201315.","journal-title":"Curr Opin Rheumatol."},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1002\/art.34624","volume":"64","author":"D Wofsy","year":"2012","unstructured":"Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64:3660\u20135.","journal-title":"Arthritis Rheum."},{"key":"621_CR33","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"The ACCESS trial group","year":"2014","unstructured":"The ACCESS trial group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheum. 2014;66:3096\u2013104.","journal-title":"Arthritis Rheum"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2014-eular.4435","volume":"73","author":"HE Fragoso-Loyo","year":"2014","unstructured":"Fragoso-Loyo HE, Dooley MA, On behalf of ACCESS Trial Group. Efficacy of the euro-lupus nephritis regimen combined with abatacept vs placebo in a North American lupus nephritis population. Ann Rheum Dis. 2014;73:77\u20138.","journal-title":"Ann Rheum Dis"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/art.37940","volume":"65","author":"D Wofsy","year":"2013","unstructured":"Wofsy D, Askanase A, Cagnoli P, Chatham W, Contreras G, Dall\u2019Era M, et al. Treatment of lupus nephritis with abatacept plus low-dose pulse cyclophosphamide followed by azathioprine (the Euro-Lupus regimen). Twenty-four week data from a double-blind controlled trial. Arthritis Rheum. 2013;65:884.","journal-title":"Arthritis Rheum"},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"IV20","DOI":"10.1161\/01.CIR.0000113708.46466.C0","volume":"109","author":"JN Cohn","year":"2004","unstructured":"Cohn JN. Introduction to surrogate markers. Circulation. 2004;109:IV20\u20131.","journal-title":"Circulation"},{"key":"621_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.00600206","volume":"1","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874\u201384.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/187153009787582388","volume":"9","author":"MH Liang","year":"2009","unstructured":"Liang MH, Simard JF, Costenbader K, Dore BT, Ward M, Fortin PR, et al. Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus. Endocr Metab Immune Disord Drug Targets. 2009;9:108\u201312.","journal-title":"Endocr Metab Immune Disord Drug Targets."},{"key":"621_CR39","unstructured":"Code of Federal Regulations, Title 21, Volume 7. Food and Drug Administration, Department of Health and Human Services. 2014. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=601.41. Accessed 10 March 2014."},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2215\/CJN.00270112","volume":"7","author":"TD McKinney","year":"2012","unstructured":"McKinney TD. Influence of decisions related to business and regulatory considerations on therapeutic development for kidney diseases. Clin J Am Soc Nephrol. 2012;7:1195\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR41","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2215\/CJN.01140113","volume":"8","author":"P Archdeacon","year":"2013","unstructured":"Archdeacon P, Shaffer RN, Winkelmayer WC, Falk RJ, Roy-Chaudhury P. Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol. 2013;8:1609\u201317.","journal-title":"Clin J Am Soc Nephrol."},{"key":"621_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4093\/dmj.2014.38.4.278","volume":"38","author":"K Woo","year":"2014","unstructured":"Woo K, Choi J, Kim B, Kim JC, Han J. Clinical usefulness of serum cystatin C as a marker of renal function. Diabetes Metab J. 2014;38:278\u201384.","journal-title":"Diabetes Metab J."},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/j.ajkd.2013.12.006","volume":"63","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63:820\u201334.","journal-title":"Am J Kidney Dis."},{"key":"621_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000018","volume":"1","author":"A Zickert","year":"2014","unstructured":"Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1, e000018.","journal-title":"Lupus Sci Med."},{"key":"621_CR45","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol."},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/keg382","volume":"42","author":"C Gordon","year":"2003","unstructured":"Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology. 2003;42:1372\u20139.","journal-title":"Rheumatology."},{"key":"621_CR47","doi-asserted-by":"crossref","unstructured":"Gladman DD. The development and initial validation of the Systemic Lupus Erythematosus International Collaborating Clinics\/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363.","DOI":"10.1002\/art.1780390303"},{"key":"621_CR48","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon GE. Danieli, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121\u201331.","journal-title":"Arthritis Rheum."},{"key":"621_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon GE, Danieli, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61\u20134.","journal-title":"Ann Rheum Dis."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0621-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0621-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:35:57Z","timestamp":1728923757000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0621-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0621-6","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"assertion":[{"value":"28 April 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"110"}}